SUBSTITUTED THIENOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F21%3A73610906" target="_blank" >RIV/61989592:15110/21:73610906 - isvavai.cz</a>
Result on the web
<a href="https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3029170/summary.html?type=number_search&tabs1Index=tabs1_1" target="_blank" >https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3029170/summary.html?type=number_search&tabs1Index=tabs1_1</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
SUBSTITUTED THIENOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE
Original language description
Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use The invention provides a new group of substituted thienopyrrolopyrimidine ribonucleosides of general formula I, wherein R is defined in the claims. The compounds of this invention show strong cytostatic and cytotoxic activities preferably against cancer cell lines of broad spectrum of diseases including tumors of various histogenetic origin.
Czech name
—
Czech description
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Patent/design ID
3029170
Publisher
CA001 -
Publisher name
Canadian Intellectual Property Office (CIPO)
Place of publication
Gatineau, Québec
Publication country
CA - CANADA
Date of acceptance
Feb 16, 2021
Owner name
Univerzita Palackého v Olomouci, Ústav organické chemie a biochemie AV ČR, v.v.i.
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence

Similar results(10)